ArticleBMC veterinary research2025
Newly isolated bacteriophages show efficacy and phage-antibiotic synergy in vitro against the equine genital pathogens Klebsiella pneumoniae and Pseudomonas aeruginosa.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy of lytic bacteriophages isolated from sewage-treatment plants in Mbarara district, Uganda against ciprofloxacin-resistant Salmonella Typhi in a mice infection model.BMC infectious diseases · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacterial infections of the genital tract are a severe problem in equine reproduction. Biofilms produced by Klebsiella (K.) pneumoniae and Pseudomonas (P.) aeruginosa present further concerns in such cases as they can limit the success of antibiotic treatments. Alternative treatment approaches are urgently needed for treating bacterial equine genital tract infections and thus, reduce antibiotic use. The present study reports on the bactericidal efficacy of both, novel K. pneumoniae- and P. aeruginosa-specific phages, in a biofilm model and in conjunction with antibiotic drugs as tested in vitro.
resultsIn total, 15 phages with lytic activity (K. pneumoniae: n = 6; P. aeruginosa: n = 9) were isolated and host ranges were determined. Four phages with a broad host range (K. pneumoniae: n = 3; P. aeruginosa: n = 1) were selected for further characterization, including electron microscopy and whole genome sequencing. Significant bacterial growth reduction was observed in planktonic killing assays at three multiplicities of infection (MOI 1, MOI 10, MOI 100), when the phages vB_KpnS_LmqsRe28-1, vB_KpnS_LmqsRe28-2, vB_KpnM_LmqsRe27-1 or vB_PaeS-LmqsRe25-1 were added. In addition, planktonic killing assays were used to examine the four phages in conjunction with gentamicin, enrofloxacin and trimethoprim-sulfadiazine in vitro. The results indicate synergistic activities between the four phages and the investigated antibiotics. However, bacterial growth was not affected in biofilm models after phage treatment, likely due the absence of depolymerase genes in the sequenced phages.
conclusionsPhages against the equine genital pathogens K. pneumoniae and P. aeruginosa were evaluated in vitro for potential clinical use. While the bactericidal activity of the isolated phages was demonstrated in liquid culture, none of the tested phages showed significant reduction in in vitro biofilm models. However, due to synergistic activities between phages and antibiotics, further studies on combinatorial approaches are needed to develop strategies for managing difficult infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.